Drug Interactions between erdafitinib and Multaq
This report displays the potential drug interactions for the following 2 drugs:
- erdafitinib
- Multaq (dronedarone)
Interactions between your drugs
dronedarone erdafitinib
Applies to: Multaq (dronedarone) and erdafitinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Coadministration with erdafitinib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme, resulting in increased toxicity or decreased efficacy of these drugs. In vitro, erdafitinib has been shown to be a time-dependent inhibitor as well as inducer of CYP450 3A4. However, no pharmacokinetic data are available from drug interaction studies.
MANAGEMENT: Concomitant use of erdafitinib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.
Drug and food interactions
dronedarone food
Applies to: Multaq (dronedarone)
Do not consume grapefruit or grapefruit juice during treatment with dronedarone unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of dronedarone to dangerous levels. This may increase the risk of an irregular heart rhythm that may be serious and potentially life-threatening, although it is a relatively rare side effect. You may be more susceptible if you have a heart condition called congenital long QT syndrome, other cardiac diseases, conduction abnormalities, or electrolyte disturbances (for example, magnesium or potassium loss due to severe or prolonged diarrhea or vomiting). Talk to your doctor if you have any questions or concerns. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or heart palpitations during treatment. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.